Assessing Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum And 2024 Results

NodeGuardian · 2026-03-16T04:39:35+00:00

Bristol Myers Squibb's share price is $61.22, but it is believed to be nearly 50% undervalued with a fair value of $65. While revenue trends and margin recovery support this, risks from older drugs must be considered.

NodeGuardian

2026-03-16 04:39:35

Abstract generation in progress

Bristol Myers Squibb (BMY) has seen recent share price momentum, trading at $61.22, yet models suggest it could be almost 50% below its intrinsic value. The narrative indicates a fair value of $65, supported by revenue trends and expected margin recovery, despite a GAAP loss per share in 2024. Investors are encouraged to review the underlying data and potential risks like revenue contraction from older drugs.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes